PL383287A1 - Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych i jej zastosowanie - Google Patents

Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych i jej zastosowanie

Info

Publication number
PL383287A1
PL383287A1 PL383287A PL38328707A PL383287A1 PL 383287 A1 PL383287 A1 PL 383287A1 PL 383287 A PL383287 A PL 383287A PL 38328707 A PL38328707 A PL 38328707A PL 383287 A1 PL383287 A1 PL 383287A1
Authority
PL
Poland
Prior art keywords
weight
lipid
carrier
production
genetic drugs
Prior art date
Application number
PL383287A
Other languages
English (en)
Other versions
PL208054B1 (pl
Inventor
Aleksander F. Sikorski
Paulina Wyrozumska
Marta Walasek
Kazimierz Kuliczkowski
Original Assignee
Uniwersytet Wrocławski
Akademia Medyczna im. Piastów Śląskich we Wrocławiu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Wrocławski, Akademia Medyczna im. Piastów Śląskich we Wrocławiu filed Critical Uniwersytet Wrocławski
Priority to PL383287A priority Critical patent/PL208054B1/pl
Priority to PCT/PL2008/000062 priority patent/WO2009031911A1/en
Publication of PL383287A1 publication Critical patent/PL383287A1/pl
Publication of PL208054B1 publication Critical patent/PL208054B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych charakteryzuje się tym, że zawiera 38,7% wagowych fosfatydylocholiny (PC), 15,4% wagowych distearoilofosfatydyloetanoloaminowej pochodnej glikolu polietylenowego 2000 (sól amonowa) (DSPE-PEG), od 10,9 do 16,8% wagowych dioleiolofosfatydyloetanolaminy (DOPE), od 4,05 do 6,75% wagowych 3ß-N-dimetyloetanokarbamoilo cholesterolu (DC-CHOL) i od 23,4 do 30,6% wagowych soli trimetyloamoniowej 1,2 -dioleilopropanu (DOTAP), przy czym PC, DOPE i DC-CHOL stanowią zewnętrzna błonę nośnika, a DOTAP wchodzi skład rdzenia nośnika zamkniętego w jego wnętrzu.
PL383287A 2007-09-06 2007-09-06 Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych i jej zastosowanie PL208054B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL383287A PL208054B1 (pl) 2007-09-06 2007-09-06 Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych i jej zastosowanie
PCT/PL2008/000062 WO2009031911A1 (en) 2007-09-06 2008-09-02 Cationic liposome carrier for genetic drugs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL383287A PL208054B1 (pl) 2007-09-06 2007-09-06 Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych i jej zastosowanie

Publications (2)

Publication Number Publication Date
PL383287A1 true PL383287A1 (pl) 2009-03-16
PL208054B1 PL208054B1 (pl) 2011-03-31

Family

ID=40325840

Family Applications (1)

Application Number Title Priority Date Filing Date
PL383287A PL208054B1 (pl) 2007-09-06 2007-09-06 Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych i jej zastosowanie

Country Status (2)

Country Link
PL (1) PL208054B1 (pl)
WO (1) WO2009031911A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013266238B2 (en) * 2012-05-23 2017-07-27 The Ohio State University Lipid-coated albumin nanoparticle compositions and methods of making and method of using the same
US10253315B2 (en) * 2012-08-30 2019-04-09 Commissariat A L'energie Atomique Et Aux Energies Alternatives Method for transfection of nucleic acids into eukaryotic cells in 3D scaffold
PL233741B1 (pl) 2014-04-18 2019-11-29 Wroclawskie Centrum Badan Eit Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja lipidowa sluzaca do wytworzenia kierowanego za pomoca przeciwcial liposomowego nosnika lekow genetycznych oraz jej zastosowanie
PL407947A1 (pl) * 2014-04-18 2015-10-26 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Ukierunkowana, liposomowa postać kompleksu oligonukleotyd-polietylenoimina, jej zastosowanie oraz sposób otrzymywania
WO2017220099A1 (en) 2016-06-24 2017-12-28 Statens Serum Institut Adjuvants with modified drainage properties
CN110101664A (zh) * 2019-05-06 2019-08-09 西安交通大学医学院第一附属医院 用于递送具有特异性剪切hpv16型基因功能的核酸类药物的系统及其制备方法
CN111603571A (zh) * 2020-05-28 2020-09-01 中国药科大学 线粒体靶向类脂质载体Mito-Aliposome、其复合物，制备方法和用途
CN114699420A (zh) * 2022-03-08 2022-07-05 南方科技大学 一种用于治疗前列腺癌组合物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2212305T3 (es) * 1997-06-23 2004-07-16 Alza Corporation Polinucleotidos encapsulados en liposomas, composicion y procedimiento.
AU2002256398A2 (en) * 2001-04-30 2002-11-11 Targeted Genetics Corporation Lipid-comprising drug delivery complexes and methods for their production
JP2007512355A (ja) * 2003-11-21 2007-05-17 アルザ コーポレイション 開裂性のｐｅｇで表面修飾されたリポソーム−ｄｎａ複合体で媒介される遺伝子送達

Also Published As

Publication number Publication date
WO2009031911A1 (en) 2009-03-12
PL208054B1 (pl) 2011-03-31

Similar Documents

Publication Publication Date Title
Mochizuki et al. The role of the helper lipid dioleoylphosphatidylethanolamine (DOPE) for DNA transfection cooperating with a cationic lipid bearing ethylenediamine
Rajesh et al. Dramatic influence of the orientation of linker between hydrophilic and hydrophobic lipid moiety in liposomal gene delivery
MX2014000053A (es) Liposomas con relacion nitrogeno:fosfato (n:p) util para el suministro de moleculas de arn.
EP4043040A8 (en) Small liposomes for delivery of immunogen-encoding rna
WO2015184256A3 (en) Biodegradable lipids for delivery of nucleic acids
WO2013093648A3 (en) Method of producing lipid nanoparticles for drug delivery
BR112013000244A2 (pt) lipossomas com lipídeos apresentando pka vantajoso para administração de rna
WO2013008240A8 (en) Liposomes co-encapsulating a bisphosphonate and an amphipathic agent
NZ729443A (en) Heterocyclic modulators of lipid synthesis
HK1205697A1 (zh) 含有羟基的药物的前药
MX2012009186A (es) Pirrolidina-2-carboxamidas sustituidas.
FI20106121A0 (fi) Soluviljelymateriaali
WO2008109031A3 (en) Liposome carriers for in vivo delivery of fullerenes
MX2014014229A (es) Pirrolidina-2-carboxamidas sustituidas.
WO2012091523A8 (en) Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof
SG195093A1 (en) Amino lipids, their synthesis and uses thereof
BR112014015333A8 (pt) composições lipossomais de clorito ou clorato
WO2012027727A3 (en) Lipomacrocycles and uses thereof
WO2010116140A8 (en) New process for preparing hydroxylamines and medicaments
WO2007048121A3 (en) Methods of preparing targeted immunoliposomes
IL313681A (en) Inhibiting ataxia telangiectasia and rad3-related protein (atr)
WO2012123482A3 (en) Isoxazolidine derivatives
WO2011064558A3 (en) Pharmaceutical composition
NZ610853A (en) Phenylketone carboxylate compounds and pharmaceutical uses thereof
WO2012159027A3 (en) Osw-1 analogs and conjugates, and uses thereof